Purple biotech to participate in canaccord genuity's 2023 horizons in oncology virtual conference

Rehovot, israel, april 18, 2023 (globe newswire) -- (globe newswire) purple biotech ltd. ("purple biotech", or the "company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (tme) to overcome tumor immune evasion and drug resistance, today announced that dr. amir horowitz, assistant professor of oncological sciences, precision immunology institute, tisch cancer institute, icahn school of medicine at mount sinai will participate on behalf of the company in a panel at canaccord genuity's 2023 horizons in oncology virtual conference on april 20, 2023 to discuss our new acquired tri-specific antibody.
PPBT Ratings Summary
PPBT Quant Ranking